Polymorphisms, hypertension and thiazide diuretics

Lorena Citterio, Chiara Lanzani, Paolo Manunta

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.

Original languageEnglish
Pages (from-to)1587-1604
Number of pages18
JournalPharmacogenomics
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Sodium Chloride Symporter Inhibitors
Hypertension
Genes
Pharmacogenetics
Human Genome
Diuretics
Prescriptions
Molecular Biology
Clinical Trials
Genome
Pharmaceutical Preparations
Therapeutics

Keywords

  • drugs
  • genes
  • hypertension
  • personalized medicine
  • sodium pump inhibitor
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Polymorphisms, hypertension and thiazide diuretics. / Citterio, Lorena; Lanzani, Chiara; Manunta, Paolo.

In: Pharmacogenomics, Vol. 12, No. 11, 11.2011, p. 1587-1604.

Research output: Contribution to journalArticle

@article{ae0c74548e7749dea587fedcec829197,
title = "Polymorphisms, hypertension and thiazide diuretics",
abstract = "It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.",
keywords = "drugs, genes, hypertension, personalized medicine, sodium pump inhibitor, therapy",
author = "Lorena Citterio and Chiara Lanzani and Paolo Manunta",
year = "2011",
month = "11",
doi = "10.2217/pgs.11.110",
language = "English",
volume = "12",
pages = "1587--1604",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - Polymorphisms, hypertension and thiazide diuretics

AU - Citterio, Lorena

AU - Lanzani, Chiara

AU - Manunta, Paolo

PY - 2011/11

Y1 - 2011/11

N2 - It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.

AB - It is 10 years since the discovery of the human genome; however, the study of the influence of genetic variants on drug effect - pharmacogenomics - has so far failed to create a major impact on day-to-day prescription practices. In the present article we analyze the main findings in candidate gene variants, gene combinations and whole-genome scans in relation to diuretic treatment. A critical analysis of the main reasons for some contrasting results will be discussed. The hypertension phases, in clinical trials dealing with genes and related pathophysiological mechanisms, may account for these inconsistent findings. The use of previously untreated versus treated patients is addressed. Finally, a positive study with a new genetic molecular strategy is described.

KW - drugs

KW - genes

KW - hypertension

KW - personalized medicine

KW - sodium pump inhibitor

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=80455174483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455174483&partnerID=8YFLogxK

U2 - 10.2217/pgs.11.110

DO - 10.2217/pgs.11.110

M3 - Article

C2 - 22044415

AN - SCOPUS:80455174483

VL - 12

SP - 1587

EP - 1604

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 11

ER -